MA46514A - Dérivés de 6- (1h-pyrazol-1-yl) pyrimidin-4-amine substitués et leurs utilisations - Google Patents
Dérivés de 6- (1h-pyrazol-1-yl) pyrimidin-4-amine substitués et leurs utilisationsInfo
- Publication number
- MA46514A MA46514A MA046514A MA46514A MA46514A MA 46514 A MA46514 A MA 46514A MA 046514 A MA046514 A MA 046514A MA 46514 A MA46514 A MA 46514A MA 46514 A MA46514 A MA 46514A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrazol
- pyrimidin
- amine derivatives
- amine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16193953 | 2016-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46514A true MA46514A (fr) | 2019-08-21 |
Family
ID=57136772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046514A MA46514A (fr) | 2016-10-14 | 2017-10-09 | Dérivés de 6- (1h-pyrazol-1-yl) pyrimidin-4-amine substitués et leurs utilisations |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US11208400B2 (fr) |
| EP (1) | EP3526212B1 (fr) |
| JP (1) | JP2019532961A (fr) |
| KR (1) | KR20190065402A (fr) |
| CN (1) | CN110191884A (fr) |
| AR (1) | AR109947A1 (fr) |
| AU (1) | AU2017341324A1 (fr) |
| BR (1) | BR112019007496A2 (fr) |
| CA (1) | CA3040166A1 (fr) |
| CL (1) | CL2019001004A1 (fr) |
| CO (1) | CO2019003761A2 (fr) |
| CR (1) | CR20190192A (fr) |
| CU (1) | CU24518B1 (fr) |
| DO (1) | DOP2019000099A (fr) |
| EA (1) | EA201990947A1 (fr) |
| EC (1) | ECSP19026563A (fr) |
| GE (1) | GEP20217269B (fr) |
| IL (1) | IL265923A (fr) |
| JO (1) | JOP20190080A1 (fr) |
| MA (1) | MA46514A (fr) |
| MX (1) | MX2019004347A (fr) |
| PE (1) | PE20191549A1 (fr) |
| PH (1) | PH12019500808A1 (fr) |
| SG (1) | SG11201903305XA (fr) |
| TN (1) | TN2019000114A1 (fr) |
| TW (1) | TW201825477A (fr) |
| UY (1) | UY37444A (fr) |
| WO (1) | WO2018069222A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110734428A (zh) * | 2019-10-24 | 2020-01-31 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
| CN115403524A (zh) * | 2021-05-26 | 2022-11-29 | 浙江省化工研究院有限公司 | 3-氟代吡唑羧酸酯、3-氟代烷基-1-取代吡唑-4-羧酸的制备方法 |
| WO2024061768A1 (fr) | 2022-09-19 | 2024-03-28 | Basf Se | Composés pesticides azolés |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| EP1175425A2 (fr) | 1999-01-21 | 2002-01-30 | The Board Of Regents, The University Of Texas System | Inhibiteurs de cotransport de na/phosphate de membrane apicale intestinale |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| DE102008020113A1 (de) * | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dihydropyrazolone und ihre Verwendung |
| ATE519759T1 (de) | 2004-12-30 | 2011-08-15 | Exelixis Inc | Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren |
| JP2010524950A (ja) * | 2007-04-16 | 2010-07-22 | セレネックス， インコーポレイテッド | テトラヒドロインドールおよびテトラヒドロインダゾール誘導体 |
| JP2008296610A (ja) | 2007-05-29 | 2008-12-11 | Toyota Motor Corp | 車両用動力伝達装置の制御装置 |
| EP2271943A1 (fr) * | 2008-04-29 | 2011-01-12 | Novartis AG | Procédés de suivi de la modulation de l'activité kinase du récepteur du facteur de croissance des fibroblastes et leurs utilisations |
| JP2012513409A (ja) | 2008-12-23 | 2012-06-14 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| US9187466B2 (en) | 2010-02-27 | 2015-11-17 | Bayer Intellectual Property Gmbh | Bisaryl-bonded aryltriazolones and use thereof |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| CA2803292C (fr) | 2010-06-30 | 2016-06-14 | Ironwood Pharmaceuticals, Inc. | Stimulateurs de sgc |
| EP2590656B1 (fr) | 2010-07-07 | 2017-11-15 | Ardelyx, Inc. | Composés et procédés permettant d'inhiber le transport du phosphate |
| EP2591354B1 (fr) * | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Composés et procédés pour l'inhibition du transport de phosphate |
| WO2012006473A1 (fr) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Composés et procédés pour l'inhibition du transport de phosphate |
| WO2012006474A2 (fr) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Composés et procédés pour l'inhibition du transport de phosphate |
| JP5827328B2 (ja) | 2010-07-07 | 2015-12-02 | アーデリクス，インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| CN103097387B (zh) | 2010-07-09 | 2016-11-02 | 拜耳知识产权有限责任公司 | 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途 |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| WO2012112363A1 (fr) | 2011-02-14 | 2012-08-23 | Merck Sharp & Dohme Corp. | Inhibiteurs de cystéine protéases, les cathepsines |
| JP6020460B2 (ja) | 2011-10-27 | 2016-11-02 | アステラス製薬株式会社 | アミノアルキル置換ｎ−チエニルベンズアミド誘導体 |
| WO2013082756A1 (fr) | 2011-12-06 | 2013-06-13 | Leo Pharma A/S | Inhibiteurs de transport de phosphate ii |
| US10150742B2 (en) | 2013-03-15 | 2018-12-11 | President And Fellows Of Harvard College | Substituted heterocyclic compounds for treating or preventing viral infections |
| WO2014181287A1 (fr) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Composés hétérocyclyliques et leurs utilisations |
| TWI582083B (zh) * | 2014-10-07 | 2017-05-11 | 美國禮來大藥廠 | 胺基吡啶基氧基吡唑化合物 |
| EA032137B1 (ru) | 2014-11-03 | 2019-04-30 | Байер Фарма Акциенгезельшафт | Производные гидроксиалкил-замещенного фенилтриазола и их применение |
| CN105631664A (zh) | 2014-11-26 | 2016-06-01 | 华为终端（东莞）有限公司 | 一种非接触支付方法、装置及系统 |
| CN107406442B (zh) * | 2014-12-23 | 2021-08-17 | 达纳－法伯癌症研究所公司 | 作为egfr抑制剂的新的嘧啶和治疗病症的方法 |
| MX2019004402A (es) | 2016-10-14 | 2019-09-26 | Inst Pasteur De Montevideo | Metodos para el tratamiento de las condiciones relacionadas con la inflamacion utilizando moduladores antiinflamatorios y metabolicos pluripotentes. |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| JP7068288B2 (ja) | 2016-10-14 | 2022-05-16 | ノバルティス アーゲー | ４－（２－（（１ｒ，２ｒ）－２－ヒドロキシシクロヘキシルアミノ）ベンゾチアゾール－６－イルオキシ）－ｎ－メチルピコリンアミドの結晶形 |
-
2017
- 2017-06-16 JO JOP/2019/0080A patent/JOP20190080A1/ar unknown
- 2017-10-09 EP EP17780751.8A patent/EP3526212B1/fr active Active
- 2017-10-09 MX MX2019004347A patent/MX2019004347A/es unknown
- 2017-10-09 PE PE2019000822A patent/PE20191549A1/es unknown
- 2017-10-09 CU CU2019000035A patent/CU24518B1/es unknown
- 2017-10-09 TN TNP/2019/000114A patent/TN2019000114A1/en unknown
- 2017-10-09 CA CA3040166A patent/CA3040166A1/fr active Pending
- 2017-10-09 CR CR20190192A patent/CR20190192A/es unknown
- 2017-10-09 WO PCT/EP2017/075630 patent/WO2018069222A1/fr unknown
- 2017-10-09 JP JP2019519748A patent/JP2019532961A/ja active Pending
- 2017-10-09 BR BR112019007496A patent/BR112019007496A2/pt not_active Application Discontinuation
- 2017-10-09 KR KR1020197013647A patent/KR20190065402A/ko not_active Application Discontinuation
- 2017-10-09 MA MA046514A patent/MA46514A/fr unknown
- 2017-10-09 CN CN201780074126.5A patent/CN110191884A/zh active Pending
- 2017-10-09 EA EA201990947A patent/EA201990947A1/ru unknown
- 2017-10-09 US US16/341,410 patent/US11208400B2/en active Active
- 2017-10-09 AU AU2017341324A patent/AU2017341324A1/en not_active Abandoned
- 2017-10-09 SG SG11201903305XA patent/SG11201903305XA/en unknown
- 2017-10-09 GE GEAP201715076A patent/GEP20217269B/en unknown
- 2017-10-12 TW TW106134859A patent/TW201825477A/zh unknown
- 2017-10-13 AR ARP170102862A patent/AR109947A1/es unknown
- 2017-10-13 UY UY0001037444A patent/UY37444A/es not_active Application Discontinuation
-
2019
- 2019-04-08 IL IL265923A patent/IL265923A/en unknown
- 2019-04-12 PH PH12019500808A patent/PH12019500808A1/en unknown
- 2019-04-12 CL CL2019001004A patent/CL2019001004A1/es unknown
- 2019-04-12 EC ECSENADI201926563A patent/ECSP19026563A/es unknown
- 2019-04-12 CO CONC2019/0003761A patent/CO2019003761A2/es unknown
- 2019-04-12 DO DO2019000099A patent/DOP2019000099A/es unknown
-
2021
- 2021-11-04 US US17/519,329 patent/US20230065629A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2019000099A (es) | 2019-07-15 |
| AU2017341324A1 (en) | 2019-05-02 |
| EA201990947A1 (ru) | 2019-08-30 |
| TW201825477A (zh) | 2018-07-16 |
| JOP20190080A1 (ar) | 2019-04-11 |
| CN110191884A (zh) | 2019-08-30 |
| EP3526212B1 (fr) | 2021-12-22 |
| WO2018069222A1 (fr) | 2018-04-19 |
| CU20190035A7 (es) | 2019-11-04 |
| US20230065629A1 (en) | 2023-03-02 |
| BR112019007496A2 (pt) | 2019-09-10 |
| CL2019001004A1 (es) | 2019-08-30 |
| ECSP19026563A (es) | 2019-04-30 |
| CO2019003761A2 (es) | 2019-04-30 |
| UY37444A (es) | 2018-05-31 |
| PE20191549A1 (es) | 2019-10-24 |
| EP3526212A1 (fr) | 2019-08-21 |
| SG11201903305XA (en) | 2019-05-30 |
| US20200055842A1 (en) | 2020-02-20 |
| IL265923A (en) | 2019-06-30 |
| TN2019000114A1 (en) | 2020-10-05 |
| CR20190192A (es) | 2019-09-02 |
| AR109947A1 (es) | 2019-02-06 |
| PH12019500808A1 (en) | 2020-01-20 |
| MX2019004347A (es) | 2019-07-01 |
| CA3040166A1 (fr) | 2018-04-19 |
| CU24518B1 (es) | 2021-06-08 |
| JP2019532961A (ja) | 2019-11-14 |
| US11208400B2 (en) | 2021-12-28 |
| KR20190065402A (ko) | 2019-06-11 |
| GEP20217269B (en) | 2021-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53400A (fr) | Hétéromultimères alk7: actriib et leurs utilisations | |
| MA43821A (fr) | Pyrimidines et variantes de celles-ci, et leurs utilisations | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| MA52483A (fr) | Dérivés de gip et leurs utilisations | |
| MA49952A (fr) | Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| MA46472A (fr) | Hétéromultimères alk4:actriib et leurs utilisations | |
| MA55044A (fr) | Hétéromultimères alk4:actriib et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| MA46471A (fr) | Protéines actriib à variant et leurs utilisations | |
| MA53145A (fr) | Agents de liaison cd123 et leurs utilisations | |
| MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
| MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
| MA44986A (fr) | Protéines de fusion gdf15 et leurs utilisations | |
| MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
| MA41598A (fr) | Composés thérapeutiques de pyridazine et leurs utilisations | |
| MA44489A (fr) | Pyrimidines et variants de celles-ci, et leurs utilisations | |
| DK3331877T3 (da) | Pyrazolpyrimidinderivat og anvendelser deraf | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| MA41460A (fr) | Agents de liaison à la tnfrsf et leurs utilisations | |
| MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
| MA45943A (fr) | Compositions ignifuges et leurs utilisations | |
| MA41898A (fr) | Dérivés de quinazolinone bicyclique | |
| MA44262A (fr) | Bioconjugués et utilisations de ceux-ci | |
| MA43567A (fr) | Anticorps pacap et leurs utilisations |